|Dr. Lindsay Allan Rosenwald||Exec. Chairman||N/A||N/A||1955|
|Dr. Lucy Lu||Pres, CEO & Director||639.78k||N/A||1975|
|Mr. Joseph Walter Vazzano||CFO, Principal Financial Officer & Company Sec.||258.78k||N/A||1984|
|Dr. Scott A. Reines||Interim Chief Medical Officer||N/A||N/A||1947|
Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was founded in 2015 and is based in New York, New York. Effective as of December 31, 2019, Avenue Therapeutics, Inc. operates as a subsidiary of InvaGen Pharmaceuticals, Inc.
Avenue Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.